# RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

> **NCT05923541** · EARLY_PHASE1 · COMPLETED · sponsor: **Henan Cancer Hospital** · enrollment: 6 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** RD13-02 cell infusion

## Key facts

- **NCT ID:** NCT05923541
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-26
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923541, "RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05923541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*